Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Centre
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Communication
In the News
Presentations
Contact Us
Contact Us
Email Alerts
In the news
Recent Posts
Recruitment of first 26 patients of Phase 2A ACCENT Trial now complete
Biotech Daily | Dr Boreham's Crucible: Amplia Therapeutics
Entitlement Offer to raise $4.27m
Proactive Interview with Dr Chris Burns
FDA clearance of Amplia's IND for pancreatic cancer trial in US
First patient dosed in phase 2a ACCENT trial
Categories
Archive
Company News
Investor Newsletters
Videos
13 Feb 2024
Proactive Interview with Dr Chris Burns
Read More
21 Nov 2023
AUSBIZ | Interview with Dr Chris Burns
Read More
20 Oct 2023
VIDEO | The Market Herald
Read More
22 May 2023
PROACTIVE INTERVIEW | Dr Chris Burns discusses Amplia's collaboration with CSIRO
Read More
06 Feb 2023
Channel 9 News | 3 February 2023
Read More
30 Jan 2023
PROACTIVE INTERVIEW | Dr Chris Burns
Read More
07 Apr 2022
VIDEO | Proactive Investors Interview, Phase 2 Clinical Trial
Read More
01 Feb 2022
VIDEO | PROACTIVE Amplia Therapeutics readies for phase two clinical trials and "watershed year" for AMP945
Read More
30 Nov 2021
VIDEO | SMALL CAPS Amplia Therapeutics makes headway in anti-cancer clinical trial
Read More
18 Nov 2021
VIDEO | PROACTIVE Amplia Therapeutics details summary results from its phase 1 clinical trial of AMP945
Read More
10 Nov 2021
VIDEO | AUSBIZ Amplia's $12M plan; what's next for the Aussie medtech
Read More
10 Nov 2021
VIDEO | Proactive Investors, $12.4m Capital Raise
Read More
29 Sep 2021
VIDEO | Proactive Lifesciences Webinar
Read More
20 Sep 2021
Proactive | Interview with Dr John Lambert
Read More
26 Jul 2021
Amplia Therapeutics phase 1 results support development of AMP945 in cancer and fibrosis
Read More
26 Jul 2021
Amplia Therapeutics develops new approach to treat cancer and fibrosis
Read More
21 Jul 2021
Amplia Therapeutics returns successful phase one trial results
Read More
19 Jul 2021
Garvan's June Seminar: The Power of Personalised Medicine
Read More
30 Jun 2021
Amplia Therapeutics partners with Garvan Institute to develop pancreatic cancer drug
Read More
28 Jun 2021
Amplia Therapeutics and Sydney’s Garvan Institute enter collaboration agreement for pancreatic cancer treatment
Read More
1
2